Sorrento Therapeutics Inc. (NASDAQ:SRNE) shares, rose in value on Thursday, 05/12/22, with the stock price up by 4.84% to the previous day’s close as strong demand from buyers drove the stock to $1.30.
Actively observing the price movement in the last trading, the stock closed the session at $1.24, falling within a range of $1.15 and $1.32. The value of beta (5-year monthly) was 2.25. Referring to stock’s 52-week performance, its high was $11.07, and the low was $1.21. On the whole, SRNE has fluctuated by -35.00% over the past month.
With the market capitalization of Sorrento Therapeutics Inc. currently standing at about $470.48 million, investors are eagerly awaiting this quarter’s results, scheduled for May 11, 2020. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.23, which is expected to increase to -$0.17 for fiscal year -$0.91 and then to about $1.66 by fiscal year 2022. Data indicates that the EPS growth is expected to be 30.00% in 2022, while the next year’s EPS growth is forecast to be 282.40%.
Analysts have estimated the company’s revenue for the quarter at $13 million, with a low estimate of $3.64 million and a high estimate of $22.36 million. According to the average forecast, sales growth in current quarter could jump up 13.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $66.97 million, representing an increase of 67.50% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that SRNE’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of SRNE currently trading nearly -21.16% and -35.96% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 31.25, while the 7-day volatility ratio is showing 11.61% which for the 30-day chart, stands at 8.73%. Furthermore, Sorrento Therapeutics Inc. (SRNE)’s beta value is 2.43, and its average true range (ATR) is 0.14. The company’s stock has been forecasted to trade at an average price of $18.00 over the course of the next 52 weeks, with a low of $16.00 and a high of $20.00. Based on these price targets, the low is -1130.77% off current price, whereas the price has to move -1438.46% to reach the yearly target high. Additionally, analysts’ median price of $18.00 is likely to be welcomed by investors because it represents a decrease of -1284.62% from the current levels.
A comparison of Sorrento Therapeutics Inc. (SRNE) with its peers suggests the former has fared considerably weaker in the market. SRNE showed an intraday change of 4.84% in last session, and over the past year, it shrunk by -79.53%%. In comparison, Exelixis Inc. (EXEL) has moved lower at -0.20% on the day and was down -22.20% over the past 12 months. On the other hand, the price of Karyopharm Therapeutics Inc. (KPTI) has fallen -1.34% on the day. The stock, however, is off -44.79% from where it was a year ago. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.13%. Meanwhile, the Dow Jones Industrial Slipped by -0.33%.
Data on historical trading for Sorrento Therapeutics Inc. (NASDAQ:SRNE) indicates that the trading volumes over the past 10 days have averaged 10.37 million and over the past 3 months, they’ve averaged 9.27 million. According to company’s latest data on outstanding shares, there are 337.12 million shares outstanding.
Nearly 6.35% of Sorrento Therapeutics Inc.’s shares belong to company insiders and institutional investors own 27.80% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 44.15 million shares as on Dec 14, 2021, resulting in a short ratio of 7.37. According to the data, the short interest in Sorrento Therapeutics Inc. (SRNE) stood at 14.41% of shares outstanding as of Dec 14, 2021; the number of short shares registered in Nov 14, 2021 reached 45.32 million. The stock has fallen by -72.04% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SRNE stock heading into the next quarter.